Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

AstraZeneca completes patient enrollment in NSCLC phase III trials of Iressa

May 10, 2001

Orally active Raf kinase inhibitor from Onyx/Bayer in phase I clinical trials

May 9, 2001

Potency of several retinoids assessed in bladder cancer cell lines

May 9, 2001

Enzon begins patient treatment in phase I trial of PEG-paclitaxel

May 9, 2001

MGI's lead acylfulvene advances to phase II for refractory sarcoma

May 9, 2001

Preclinical profile of Bay-59-8862, a new taxane, reviewed in Drugs of the Future

May 8, 2001

MAbs prepared at Genentech act as HGF receptor antagonists

May 8, 2001

Cell Pathways and BMS to initiate drug combination study for first-line NSCLC

May 8, 2001

Preclinical antiproliferative activity of A-105972 characterized

May 8, 2001

Phase II trial of irofulven for treatment of glioma commences

May 8, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...